These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 14723609)

  • 1. Systematic review: short-term adverse effects of 5-aminosalicylic acid agents in the treatment of ulcerative colitis.
    Loftus EV; Kane SV; Bjorkman D
    Aliment Pharmacol Ther; 2004 Jan; 19(2):179-89. PubMed ID: 14723609
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis.
    Feagan BG; Macdonald JK
    Cochrane Database Syst Rev; 2012 Oct; 10():CD000544. PubMed ID: 23076890
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis.
    Wang Y; Parker CE; Feagan BG; MacDonald JK
    Cochrane Database Syst Rev; 2016 May; 2016(5):CD000544. PubMed ID: 27158764
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A double-blind comparison of balsalazide, 6.75 g, and sulfasalazine, 3 g, as sole therapy in the management of ulcerative colitis.
    Mansfield JC; Giaffer MH; Cann PA; McKenna D; Thornton PC; Holdsworth CD
    Aliment Pharmacol Ther; 2002 Jan; 16(1):69-77. PubMed ID: 11856080
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Low dose balsalazide (1.5 g twice daily) and mesalazine (0.5 g three times daily) maintained remission of ulcerative colitis but high dose balsalazide (3.0 g twice daily) was superior in preventing relapses.
    Kruis W; Schreiber S; Theuer D; Brandes JW; Schütz E; Howaldt S; Krakamp B; Hämling J; Mönnikes H; Koop I; Stolte M; Pallant D; Ewald U
    Gut; 2001 Dec; 49(6):783-9. PubMed ID: 11709512
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A meta-analysis of the efficacy of sulfasalazine in comparison with 5-aminosalicylates in the induction of improvement and maintenance of remission in patients with ulcerative colitis.
    Nikfar S; Rahimi R; Rezaie A; Abdollahi M
    Dig Dis Sci; 2009 Jun; 54(6):1157-70. PubMed ID: 18770034
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of mesalazine in acute and long-term treatment of ulcerative colitis and its complications.
    Schroeder KW
    Scand J Gastroenterol Suppl; 2002; (236):42-7. PubMed ID: 12408503
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Maintenance of remission of ulcerative colitis: a comparison between balsalazide 3 g daily and mesalazine 1.2 g daily over 12 months. ABACUS Investigator group.
    Green JR; Gibson JA; Kerr GD; Swarbrick ET; Lobo AJ; Holdsworth CD; Crowe JP; Schofield KJ; Taylor MD
    Aliment Pharmacol Ther; 1998 Dec; 12(12):1207-16. PubMed ID: 9882028
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A randomized, double blind, dose-response comparison of balsalazide (6.75 g), balsalazide (2.25 g), and mesalamine (2.4 g) in the treatment of active, mild-to-moderate ulcerative colitis.
    Levine DS; Riff DS; Pruitt R; Wruble L; Koval G; Sales D; Bell JK; Johnson LK
    Am J Gastroenterol; 2002 Jun; 97(6):1398-407. PubMed ID: 12094857
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of mesalazine and balsalazide in induction and maintenance of remission in patients with ulcerative colitis: a meta-analysis.
    Rahimi R; Nikfar S; Rezaie A; Abdollahi M
    Dig Dis Sci; 2009 Apr; 54(4):712-21. PubMed ID: 18683049
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A double-blind comparison of balsalazide, 6.75 g daily, and sulfasalazine, 3 g daily, in patients with newly diagnosed or relapsed active ulcerative colitis.
    Green JR; Mansfield JC; Gibson JA; Kerr GD; Thornton PC
    Aliment Pharmacol Ther; 2002 Jan; 16(1):61-8. PubMed ID: 11856079
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis.
    Feagan BG; Macdonald JK
    Cochrane Database Syst Rev; 2012 Oct; 10():CD000543. PubMed ID: 23076889
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Balsalazide is superior to mesalamine in the time to improvement of signs and symptoms of acute mild-to-moderate ulcerative colitis.
    Pruitt R; Hanson J; Safdi M; Wruble L; Hardi R; Johanson J; Koval G; Riff D; Winston B; Cross A; Doty P; Johnson LK
    Am J Gastroenterol; 2002 Dec; 97(12):3078-86. PubMed ID: 12492193
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Balsalazide: a review of its therapeutic use in mild-to-moderate ulcerative colitis.
    Muijsers RB; Goa KL
    Drugs; 2002; 62(11):1689-705. PubMed ID: 12109930
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Review article: balsalazide therapy in ulcerative colitis.
    Ragunath K; Williams JG
    Aliment Pharmacol Ther; 2001 Oct; 15(10):1549-54. PubMed ID: 11563993
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Olsalazine versus mesalazine in the treatment of mild to moderate ulcerative colitis.
    Kruis W; Brandes JW; Schreiber S; Theuer D; Krakamp B; Schütz E; Otto P; Lorenz-Mayer H; Ewe K; Judmaier G
    Aliment Pharmacol Ther; 1998 Aug; 12(8):707-15. PubMed ID: 9726382
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Balsalazide is more effective and better tolerated than mesalamine in the treatment of acute ulcerative colitis. The Abacus Investigator Group.
    Green JR; Lobo AJ; Holdsworth CD; Leicester RJ; Gibson JA; Kerr GD; Hodgson HJ; Parkins KJ; Taylor MD
    Gastroenterology; 1998 Jan; 114(1):15-22. PubMed ID: 9428213
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Balsalazide.
    Prakash A; Spencer CM
    Drugs; 1998 Jul; 56(1):83-9; discussion 90. PubMed ID: 9664201
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oral balsalazide (Colazal) for ulcerative colitis.
    Med Lett Drugs Ther; 2001 Jul; 43(1109):62-3. PubMed ID: 11468602
    [No Abstract]   [Full Text] [Related]  

  • 20. The systemic load and efficient delivery of active 5-aminosalicylic acid in patients with ulcerative colitis on treatment with olsalazine or mesalazine.
    Støa-Birketvedt G; Florholmen J
    Aliment Pharmacol Ther; 1999 Mar; 13(3):357-61. PubMed ID: 10102969
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.